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Abstract
Background: Insect‐bite hypersensitivity (IBH) in horses is a chronic allergic dermati-
tis caused by insect bites. Horses suffer from pruritic skin lesions, caused by type‐I/
type‐IV allergic reactions accompanied by prominent eosinophil infiltration into the
skin. Interleukin‐5 (IL‐5) is the key cytokine for eosinophils and we have previously
shown that targeting IL‐5 by vaccination reduces disease symptoms in horses.
Objective: Here, we analyzed the potential for long‐term therapy by assessing a
second follow‐up year of the previously published study.
Methods: The vaccine consisted of equine IL‐5 (eIL‐5) covalently linked to a cucumber
mosaic virus‐like particle (VLP) containing a universal T cell epitope (CuMVTT) using a
semi‐crossover design to follow vaccinated horses during a second treatment season.
Thirty Icelandic horses were immunized with 300 μg of eIL‐5‐CuMVTT without adjuvant.
Results: The vaccine was well tolerated and did not reveal any safety concerns through-
out the study. Upon vaccination, all horses developed reversible anti‐eIL‐5 auto‐anti-
body titers. The mean course of eosinophil levels was reduced compared to placebo
treatment leading to significant reduction of clinical lesion scores. Horses in their second
vaccination year showed a more pronounced improvement of disease symptoms when
compared to first treatment year, most likely due to more stable antibody titers induced
by a single booster injection. Hence, responses could be maintained over two seasons
and the horses remained protected against disease symptoms.
Conclusion: Yearly vaccination against IL‐5 may be a long‐term solution for the
treatment of IBH and other eosinophil‐mediated diseases in horses and other
species including humans.
K E YWORD S
allergic dermatitis, eosinophils, vaccination
Abbreviations: CuMV, cucumber mosaic virus-derived virus-like particles; CuMVTT, CuMV containing a tetanus toxoid universal T cell epitope tt830-843; eIL-5, equine IL-5; IBH, insect-bite
hypersensitivity; ISI, insect-bite hypersensitivity severity index; VLP, virus-like particle.
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1 | INTRODUCTION
Insect‐bite hypersensitivity (IBH) in horses is caused by an allergy
against insect bites, more specifically against Culicoides spp. It is a
severe and chronic disease affecting a large number of horses world-
wide. Although IBH is the best characterized allergic dermatitis in
horses, effective treatment is still lacking.1–8 We recently proposed a
new therapeutic vaccination targeting eosinophils by active vaccina-
tion against IL‐5.9 Host‐made auto‐antibodies induced by active vac-
cination show overall similar advantages and safety profiles as
monoclonal antibodies (mAb) administered via passive vaccination. A
major drawback of mAbs is the potential induction of anti‐mAb anti-
bodies and their relative short half‐life, thus limiting its clinical
long‐term use. On the other hand, a specific concern of therapeutic
vaccines is the potential irreversibility of the antibody responses,
potentially causing lifelong blockage of target self‐molecules.10 The
most prominent therapeutic vaccine in veterinary use is the anti‐boar
vaccine Improvac®, targeting gonadotropin‐releasing hormone
(GnRH).11 A similar immunocontraceptive vaccine was developed for
horses, known as GonaCon‐Equine™,12 registered in the US for
female wild/feral horses and burros. For human use, a number of
anti‐self vaccines are in preclinical and clinical development mostly
targeting cytokines in inflammatory conditions and personalized anti‐
cancer vaccines.13,14
Originally described as an IgE‐dependent type‐I allergy, it has
recently emerged that IBH also shows characteristics of a delayed‐
type hypersensitivity (DTH) allergic response. Eosinophils may be a
common denominator, as they can play a key role in both allergic
reactions. Indeed, allergic lesions are characterized by strong eosino-
philic inflammation9,15 and it has previously been suggested that
eosinophils strongly contribute to IBH disease pathology.16 This
notion is supported by the fact that increased expression of IL‐4, IL‐
5, and IL‐13 mRNA is found in acute lesions. IL‐5 is the key cytokine
for the development, survival, and activation of eosinophils. In addi-
tion, established lesions show enhanced levels of mRNA encoding
the chemokines CCL11 (Eotaxin‐1) and CCL2 (monocyte chemotactic
protein 1 (MCP1)).17 Eotaxin‐1 is a potent eosinophil chemoattrac-
tant and binds to the CCR3 receptor. Furthermore, Eotaxin‐1 is
involved in eosinopoiesis and cooperates with IL‐5 at inducing blood
eosinophilia.18,19 Together with IL‐5, Eotaxin‐1 stimulates eosinophils
to migrate from blood to tissue19 and locally produce a large number
of pro‐inflammatory and toxic mediators.17,20 We recently found
that eosinophils are not only upregulated locally within lesions but
also systemically in blood and that these blood eosinophil levels
strongly correlate with disease severity.9 Hence, blood eosinophilia
might be a new and easy‐to‐measure diagnostic disease activity mar-
ker of IBH and related diseases.
In order to target eosinophils, we developed a therapeutic vac-
cine targeting equine IL‐5 (eIL‐5). IL‐5 is a classical Th2 cytokine and,
as discussed above, is the master regulator for eosinophil‐mediated
inflammation.18,21,22 Hence, IL‐5 is known to be an eosinophil line-
age‐specific cytokine, thereby having limited effects on other lin-
eages.23 In contrast to the veterinary field, IL‐5 blocking agents are
already well known for use in human hyper‐eosinophilic conditions
such as eosinophilic asthma. Three monoclonal antibodies, two
blocking IL‐5 directly (Reslizumab and Mepolizumab), and one block-
ing the IL‐5Rα (Benralizumab) received market authorization over the
past two years. All IL‐5 pathway interfering antibodies and in partic-
ular both anti‐IL‐5 antibodies have a very good safety profile col-
lected over the past 10 years of clinical testing and use.24
In order to induce IL‐5‐specific neutralizing antibodies, we have
developed a virus‐like particle (VLP)‐based IL‐5 vaccine, which can
overcome B cell unresponsiveness.9,25 Our previously published
study shows that vaccination of horses resulted in high levels of
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IL‐5‐specific antibodies and statistically significant reductions of
lesion scores in vaccinated IBH‐affected horses when compared to
placebo‐treated IBH‐affected horses.9 Here, we document a follow‐
up study subsequent to the placebo‐controlled double‐blind study of
the 1st year. The current study was performed in the 2nd year with
a semi‐crossover design. Three main questions were addressed. (a)
Assess the impact of reducing basic vaccination injections in the first
treatment year from five to three injections and in the second treat-
ment year to a single booster injection at the beginning of the sea-
son; (b) compare eosinophil levels in previously placebo‐treated
horses and first year vaccination of the same horses; (c) investigate
long‐term treatment potential. We report that basic vaccination con-
sisting of three injections with eIL‐5‐CuMVTT reduces eosinophil
levels in blood. Furthermore, a single booster may be suitable for
long‐term management of IBH and other eosinophil‐mediated dis-
eases in horses. This suggests that comparable vaccines may be
developed for other species including eosinophilic asthma in humans.
2 | MATERIALS & METHODS
2.1 | Horses & clinical study design
All study horses were Icelandic horses and were privately held by
their owners. All clinical studies had been approved by the respec-
tive cantonal veterinary authorities. All horse owners signed
informed consent. The clinical study was a semi‐crossover follow‐up
of a double‐blind placebo‐controlled randomized trial, in which all
horses received vaccine, either as a first year treatment (following
placebo treatment) or as a second year treatment. Thirty‐four Ice-
landic horses had been recruited to the two‐year placebo‐controlled
double‐blind randomized clinical study that has been described previ-
ously9: The study consisted of 2 years, an observational year (“Pre‐
season”) and a treatment year (“1st year”). Thirty horses were then
recruited to the here‐described semi‐crossover follow‐up year (“2nd
year”) when all horses received the eIL‐5‐CuMVTT vaccine. Thirteen
horses previously treated with placebo received a basic vaccination
regimen consisting of two vaccinations in January (week 0) and
February (week 4) and one booster immunization in June (week 19;
Group 1); and 17 previously immunized horses received a single
booster immunization at season start in March (week 6; Group 2;
Figure S1). Of note, three horses of the previously immunized Group
2 received a second booster because of low anti‐IL‐5 titers. In order
to reduce the number of injections during basic vaccination year, we
now altered injection frequency and regimen in Group 1 horses to
three vaccinations in weeks 0, 4, and 19, in contrast to the previous
five injections in weeks 0, 4, 8, 12, and 19 in 1st year treatment of
Group 2 horses.9 Vaccine was administered subcutaneously without
the presence of adjuvants. In the observational year (“Pre‐season”),
the eczema lesions of all horses had been recorded monthly (after
study recruitment) and blood eosinophil levels and a serum IgE
against insects had been determined at a single time point. In both
treatment years (“1st year” and “2nd year”) before vaccination and at
the end of each study year, health status in blood and parasite levels
in stool of all horses were determined. During the treatment years,
all horses were bled monthly in order to monitor antibody titers and
eosinophil levels. Additionally, eczema lesions were scored at least
monthly.
2.2 | IBH lesion scoring
Described in Ref. 9.
2.3 | Blood withdrawal
Blood was collected from V. jugularis at the intersection of the prox-
imal to median third of the neck.
2.4 | Blood analysis by IDEXX Diavet and
production of horse sera and plasma
Blood was collected into tubes provided by IDEXX Diavet (Switzer-
land). Differential blood analysis was done using fresh EDTA blood,
measured by IDEXX Diavet.
2.5 | Anti‐CuMVTT and anti‐IL‐5 antibody titer
determination
Described in Ref. 9.
2.6 | Cloning, expression and purification of
recombinant eIL‐5
Described in Ref. 9.
2.7 | Coupling of eIL‐5 to CuMVTT
Described in Ref. 9. Briefly, CuMVTT VLP reacted with a 10‐fold molar
excess of the heterobifunctional cross‐linker succinimidyl‐6(β‐maleimi-
dopropionamido)hexanoate (SMPH) in 20 mmol/L NaP/2 mmol/L
EDTA, pH 7.5 at 25°C (Pierce). Unreacted cross‐linker was removed
by passage over a PD‐10 desalting column (GE Healthcare). The
recombinant, purified and refolded eIL‐5‐C‐His, was reduced for
1 hour with an equimolar amount of tri(2‐carboxyethyl)phosphine
hydrochloride (TCEP) in 20 mmol/L NaP/2 mmol/L EDTA, pH 7.5 to
reduce the cysteine residue contained in the linker. The reduced eIL‐5‐
C‐His was then mixed with the derivatized CuMVTT VLPs at a molar
ratio of 2:1 (monomer IL‐5:monomer VLP) and co‐incubated for
4 hours at 22°C in 20 mmol/L NaP/2 mmol/L EDTA, pH 7.5 to allow
cross‐linking. Vaccine was purified on a HiLoad 26/600 Superdex 75
prep grade (GE Healthcare) with 20 mmol/L NaP/2 mmol/L EDTA, pH
7.5 in order to remove free unbound eIL‐5. Protein concentration was
determined by Bradford assay to BSA standard.
2.8 | SDS‐PAGE & Coomassie staining
Described in Ref. 9.
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2.9 | Western blot
Described in Ref. 9.
2.10 | Vaccine administration, immunization
regimen
In order to generate self‐reactive antibodies to equine IL‐5, horses
were injected subcutaneously with 300 μg of eIL5‐C‐His‐CuMVTT VLP
in 1000 μL of 20 mmol/L NaP/2 mmol/L EDTA, pH 7.5 without addi-
tional adjuvants. Horses, that had received vaccine in the previous sea-
son (Group 2), received a single booster at the beginning of March
(n = 17), whereof three horses received an additional booster in June
(week 19). Horses, that had received placebo in the previous season
(Group 1), received a prime‐boost vaccination in weeks 0 (January), 4
(February) and a booster in week 19 (June; n = 13).
2.11 | Linear epitope mapping
Linear epitope mapping using serum of three different eIL‐5‐VLP
vaccinated horses was performed by PEPperPRINT GmbH, Heidel-
berg, Germany. Negative control was naive serum prior to vaccina-
tion.
2.12 | Model structure equine IL‐5 dimer
The monomeric equine IL‐5 was plotted onto the dimeric human
IL‐5 crystal structure using Pymol. The monomeric eIL‐5 structure
was calculated by Kallber et al.26
2.13 | Model structures for IL‐5 and IL‐5Rα
Structure of human IL‐5 dimer binding to its human IL‐5Rα27 was used
as a template for the generation of a model structure of equine IL‐5
dimer binding to the human IL‐5Rα by Pymol. Human and equine IL‐5
dimer was illustrated including epitope of Reslizumab (Ref. 28) binding
site (yellow) and major epitope site of equine IL‐5 (magenta) resulting
from linear epitope mapping by PEPperPRINT.
2.14 | Parasitic presence
Described in Ref. 9. Worm parasites were distinguished for nema-
tode (roundworms), cestoda oocysts (tapeworms), and tapeworm
eggs/body parts. All horse owners maintained their individual anti‐
helminthic treatment regimen over all seasons, depending on the
individual helminth concept (according to recommendations: either
helminth monitoring with a single dewormer/y or three dewormers/y).
2.15 | Statistics
All graphs comparing vaccinated horses vs placebo horses show mean
and standard error of mean (SEM). Statistical analysis was performed
by paired, one‐tailed non‐parametric Wilcoxon test. Considered to be
statistically significant were P‐values lower than 0.05: *P < 0.05;
**P < 0.01; ***P < 0.001.
3 | RESULTS
3.1 | Vaccine preparation
Recombinant eIL‐5 with a C‐terminal linker containing a free cysteine
residue and a His‐Tag (eIL‐5‐C‐His) was produced in Escherichia coli
and purified by affinity chromatography, refolded, and polished by
size‐exclusion chromatography as described in Ref. 9. The eIL‐5‐C‐
His homodimers were then chemically coupled to VLPs derived from
the cucumber mosaic virus (CuMVTT) Ref. 9 via the heterobifunc-
tional cross‐linker SMPH. Derivatization of the VLP shows the typi-
cal “VLP‐ladder” with CuMV monomeric and multimeric subunits
(Figure S2A, lane 2) caused by cross‐linking of VLP‐internal Cys and
Lys Ref. 9. Coupling of CuMV subunits with dimeric eIL‐5‐C‐His
molecules (Figure S2A, lane 1) is shown on a reducing SDS‐PAGE gel
by the presence of additional coupling bands that correspond to the
molecular mass of monomeric or dimeric eIL‐5 plus monomeric or
multimeric CuMV subunits (Figure S2A, lane 3). Successful covalent
attachment of eIL‐5‐C‐His to CuMVTT was confirmed by Coomassie
staining (Figure S2A) and Western blot using an anti‐His antibody,
thus staining only His‐tagged eIL‐5 (Figure S2B). Coupling efficiency
for all batches was between 40% and 70% (ie, between 70 and 120
IL‐5 molecules were displayed per VLP). A further vaccine polishing
step by size‐exclusion chromatography was performed to remove
free uncoupled eIL‐5 from the vaccine (Figure S2A and B, lane 4 and
Figure S2A and B, lane 5).
3.2 | Antibody titer responses upon vaccination
Antibody titers in serum of horses were evaluated once per month.
Thirteen previously placebo‐treated horses (Group 1) received a
basic vaccination consisting of three immunization, and 17 previously
immunized horses (Group 2) received a single boost at the beginning
of the season. Three horses of Group 2 had received an additional
booster in June. One vaccine dose contained 300 μg of eIL‐5‐
CuMVTT (based on CuMV protein, corresponding to about 150 μg of
displayed eIL‐5) formulated in sodium phosphate buffer without
adjuvants. Anti‐CuMVTT antibody titers were used as surrogate mar-
ker for successful vaccination as the immune system is expected to
readily induce antibodies against the foreign CuMVTT particles. In
total, 30 out of 30 vaccinated horses developed antibodies against
both IL‐5 and CuMVTT. However, the Group 1 horses which were
de novo immunized with three doses (Figure 1A and C) showed
higher but less stable anti‐IL5 titers than the horses receiving a sin-
gle booster immunization (Group 2) (Figure 2A and C). Antibody titer
against eIL‐5 and CuMVTT can be observed in all naive horses upon
eIL‐5‐CuMVTT vaccination already after the second vaccine injection
(Figure 2). All de novo immunized Group 1 horses developed anti‐IL‐
5 antibody titers, suggesting that the vaccination regimen of two
injections prior to IBH season plus one booster in the middle of the
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season is sufficient for auto‐antibody induction and maintenance in
first season horses. After having reached high anti‐IL‐5 titers upon
the two initial vaccinations, antibody titers continuously dropped.
The booster injection efficiently increased the antibody titer in mid‐
season (Figure 1A and B). Anti‐CuMVTT titers followed the same pat-
tern; however, peak levels were lower when compared to anti‐IL‐5
levels, indicating that the immune response was dominated by anti‐
IL‐5 (Figure 1C and D).
In the boosted Group 2 horses, all horses developed antibodies
against IL‐5 and CuMVTT. Importantly, the single booster at season
start for Group 2 was sufficient to induce long‐lasting anti‐IL5 anti-
bodies throughout the season in almost all of the horses (Fig-
ure 2A and C). Interestingly, after induction of anti‐IL‐5 antibodies,
titers were decreasing only slightly to reach a steady‐state during
IBH season and only dropped toward season's end. Anti‐CuMVTT
antibody titers showed an overall similar pattern and increased
upon vaccination before they slowly but continuously declined
(Figure 2B and D).
Although anti‐IL‐5 antibody titers between single horses were
slightly more variable than antibody titers against the carrier VLP,
both antibody responses correlated well overall (Figures 1E and 2E),
demonstrating that anti‐CuMVTT titers do not interfere with the
induction of anti‐IL‐5 antibodies.
3.3 | Antibody specificity assessed by linear
epitope mapping
Linear epitope mapping by PEPperPRINT (PEPperCHIP Custom Pep-
tide Microarray, Heidelberg, Germany)29 from serum of three eIL‐5‐
VLP vaccinated horses showed three epitopes, whereof one major
epitope was recognized by all three horses tested. Each of the two
minor epitopes was recognized by two horse sera (Figures 3A and
S3). Structural models of dimeric eIL‐5 based on dimeric human IL‐5
(huIL‐5) crystal structure place the major epitope in a loop, and both
minor epitopes in two different alpha helices (Figure 3B, magenta:
loop—GNLMI, blue: α‐helices—EEVFQGIDT, cyan: α‐helices—
MNRLVAETLT). As expected, the surface structural model of dimeric
eIL‐5 shows that all epitopes are exposed on the surface of the
molecule and thus accessible to antibodies (Figure 3C). Mapping of
the dimeric eIL‐5 model onto the human IL‐5 receptor 5 alpha (huIL‐
5Rα) with the recognized epitopes marked is shown in Figure 3D. In
parallel, the dimeric huIL‐5 was mapped onto the huIL‐5Rα (Fig-
ure 3E). Furthermore, the huIL‐5 epitope, which is recognized by the
registered anti‐huIL‐5 neutralizing antibody reslizumab (Ref. 28), is
displayed on the dimeric huIL‐5. Interestingly, the epitopes on the
huIL‐5 recognized by reslizumab were similar regions compared to
the epitopes recognized by the sera of vaccinated horses. The data
F IGURE 1 Antibody titer of Group 1
horses against eIL‐5 and CuMVTT‐VLP.
Vaccinations are indicated by gray arrows.
A, Mean antibody titer of anti‐eIL‐5 IgG. B,
Mean antibody titer of anti‐CuMV IgG. C,
Antibody titer of anti‐eIL‐5 IgG of single
horses. D, Antibody titer of anti‐CuMV IgG
of single horses. All antibody titers are
calculated with naive serum subtracted on
logarithmic scales, limit of detection is
titers ≤10. E, Correlation of anti‐CuMV IgG
and anti‐IL‐5 IgG antibody titer of single
horses, 13 horses and 10 time points each
(from January until October). VLP, virus‐
like particle
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presented rely on in silico interaction between eIL‐5 and the huIL‐5‐
IL‐5Rα receptor (modeled by the hu IL‐5‐IL‐5Rα interaction) and their
predictive value may therefore be limited. However, the model
reveals a comparable binding site found in the human analogous,
which indeed strongly suggests induction of neutralization antibodies
upon eIL‐5‐CuMVTT vaccination (Figure 3D and E: magenta—major
equine epitope, yellow—reslizumab epitope).
3.4 | Blood eosinophilia
Eosinophil levels were measured once per month in all horses. The
data were analyzed according to intention to treat (ITT), thus
including all horses, without exclusion of animals. The de novo
immunized Group 1 horses that were vaccinated twice in January
and February followed by a booster vaccination in June showed
statistically significant reduction of eosinophil levels throughout the
treatment season (Figure 4A, black circles) compared to the pla-
cebo‐treated first season (Figure 4A, gray circles). Group 2 horses
had received five immunizations in the previous “1st year” season
and a single booster vaccination in the follow‐up “2nd year” in
March just before the season started. However, three horses of
Group 2 with low anti‐IL‐5 titers received an additional boost in
June. As expected, Group 2 horses showed comparable blood eosi-
nophil levels throughout both vaccinated seasons (Figure 4B). How-
ever, there was an unexpected spike of eosinophils early in the
first treatment year (Figure 4B, “1st year,” filled circles), which
remains unexplained but perhaps was due to free eIL‐5 present in
the earlier vaccine preparation. Most importantly, the course of
eosinophil levels negatively correlated with antibody levels, indicat-
ing that anti‐IL‐5 antibodies likely caused the reduction of eosino-
phil levels (Figures 1 and 4A,C).
3.5 | Reduced IBH lesion scores in eIL‐5‐CuMVTT
vaccinated horses
Lesion scores for all horses were recorded at least once per month
from March until October. The data were analyzed according to
ITT, thus including all horses that participated during all three sea-
sons: ie, (a) Pre‐treatment; (b) first year treatment/placebo; (c) sec-
ond year treatment/first year treatment. Seasonal progression of
lesion scores of Group 1 horses was comparable to “Pre‐season”
and placebo treatment during “1st year.” However, upon vaccina-
tion during “2nd year,” lesion scores over the season clinically
improved highly significantly (Figure 5A). Comparably, Group 2
F IGURE 2 Antibody titer of Group 2
horses against eIL‐5 and CuMVTT‐VLP.
Vaccinations are indicated by gray arrows.
A, Mean antibody titer of anti‐eIL‐5 IgG. B,
Mean antibody titer of anti‐CuMV IgG. C,
Antibody titer of anti‐eIL‐5 IgG of single
horses. D, Antibody titer of anti‐CuMV IgG
of single horses. All antibody titers are
calculated with naive serum subtracted on
logarithmic scales, limit of detection is
titers ≤10. E, Correlation of anti‐CuMV IgG
and anti‐IL‐5 IgG antibody titer of single
horses, 17 horses and eight time points
each (from April until October). VLP, virus‐
like particle
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horses had been vaccinated using eIL‐5‐CuMVTT in both seasons
“1st year” and “2nd year” and showed a statistically significant
improved course of lesion scores in both vaccinated years when
comparing to their “Pre‐season” or placebo‐treated horses. More-
over, lesion course of Group 2 horses even further improved in the
second year treatment when compared to first year treatment
(Figure 5B). Area under the curve (AUC) of mean average lesions
scores per year of both groups (Figure 5C), average lesion scores
for single horses (Figure 5D), and mean average lesion score per
year (Figure 5E Group 1, Figure 5F Group 2) also showed improve-
ment of lesions scores upon vaccination with even enhanced
improvement during the second treatment year.
F IGURE 3 Antibody specificity by
linear epitope mapping. A‐D, Colored
epitopes recognized by vaccine‐induced
self‐antibodies, major epitope: magenta
(loop—GNLMI), minor epitope 1: blue (α‐
helices—EEVFQGIDT), minor epitope 2:
cyan (α‐helices—MNRLVAETLT); eIL‐5
monomers in green, disulfide bridges in red
and orange. A, Linear amino acid sequence
of eIL‐5 with colored linear epitopes. B,
Structure model of dimeric eIL‐5 based on
calculated monomeric eIL‐5 plotted on the
human dimeric crystal structure. C, Surface
model of dimeric eIL‐5 based on calculated
monomeric eIL‐5 plotted on the human
dimeric crystal structure. D, Mapping of
the dimeric eIL‐5 model onto the human
IL‐5 receptor 5 alpha (huIL‐5Rα) with
marked epitopes of reslizumab (yellow) and
corresponding equine epitopes. E, Mapping
of the dimeric huIL‐5 onto the huIL‐5Rα
with marked epitopes of reslizumab
(yellow) and corresponding equine epitopes
F IGURE 4 Course of eosinophil levels in blood. A, Course of seasonal blood eosinophil levels in Group 1 horses of placebo‐treated season
(gray circles, n = 13) and 1st year vaccination season in “2nd year” (black circles, n = 13). B, Course of seasonal blood eosinophil levels in
Group 2 horses of 1st year vaccination season (filled circles, n = 17) and 2nd year vaccination season (empty circles, n = 17). C, Correlation of
eosinophil levels in blood vs anti‐IL‐5 antibody levels shown by area under the curve (AUC) from Group 1 horses
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Analogous to the Psoriasis Area and Severity Index (PASI) used
in human psoriasis patients, the IBH Severity Index (ISI) 50 and ISI
75 score describes the percentage of horses that improved their IBH
symptoms ≥50% or ≥75%, respectively. The ISI score data only
include horses, which were present in the current follow‐up “2nd
year” study (n = 30) and compared scores between all 3 years. In the
first treatment year, 53% of vaccinated horses reached an ISI 50,
whereas only 8% in the placebo group reached the ISI 50. An ISI 75
was reached by 23% of vaccinated horses. No placebo‐treated horse
reached ISI 75 (Figure 6A). In the second treatment year, 69% of de
novo immunized Group 1 horses and 88% of Group 2 horses
reached an ISI 50. An ISI 75 was reached by 31% of Group 1 horses
and by 47% of Group 2 horses (Figure 6B).
3.6 | No increase in parasite presence after eIL‐5‐
CuMVTT vaccination and no other side effects
Due to the known protective role of eosinophils during helminth infec-
tions, parasite presence in horse excrement was recorded before and
after the season for all animals in both treatment years. No difference
of parasite presence was detected between prior to (pre) and post
(post) vaccination in 1st year and 2nd year (Figure S4A). Delta
F IGURE 5 Improving IBH lesion scores by vaccination with eIL‐5‐CuMVTT vaccine. A & B, Mean monthly lesion score from March until
October in “Pre‐evaluation” year (n = 34), “1st year” (placebo‐controlled double‐blind randomized study, n = 34), and “2nd year” (half crossover
follow‐up vaccination, n = 30). Months with more than one measurement show mean values. A, Group 1 horses in “Pre‐season” (dotted gray
line, n = 15), blinded placebo treatment “1st year” (continuous gray line, n = 15), and first season with vaccine treatment “2nd year” (dotted
black line, n = 13). B, Group 2 horses in “Pre‐season” (dotted gray line, n = 19), blinded vaccine treatment “1st year” (dotted black line, n = 19),
and follow‐up second year vaccine treatment (continuous black line, n = 17). C, Area under the curve of mean average lesion score per year of
Group 1 (empty circles) and Group 2 (filled circles). D, Average (of monthly mean) lesion score per year of single horses in Group 2 (black lines)
and Group 1 (gray lines) during “Pre‐season” (pre), placebo treatment or eIL‐5‐CuMVTT vaccination “1st year,” and eIL‐5‐CuMVTT vaccination
“2nd year”. E, Mean average lesion score of all Group 1 horses during “Pre‐season” year (pre, gray pattern, n = 15), blinded placebo treatment
“1st year” (filled gray, n = 15), and eIL‐5‐CuMVTT vaccination “2nd year” (filled black, n = 13). F, Mean average lesion score of all Group 2
horses during “Pre‐season” (pre, gray pattern, n = 19), blinded first year eIL‐5‐CuMVTT vaccination “1st year” (filled black, n = 19), and follow‐
up eIL‐5‐CuMVTT vaccination “2nd year” (black pattern, n = 17). All graphs include all horses, n = 34 (“Pre‐season”, “1st year”), n = 30 (“2nd
year”), independent of antibody titer: ITT, intention to treat; IBH, insect‐bite hypersensitivity
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helminth presence of post‐ and pre‐vaccination is comparable
between Group 1 and Group 2 in “1st year” and “2nd year,” with a ten-
dency toward lower helminthes in 2nd year vaccinated horses of
Group 2 (Figure S4B). In general, however, helminth presence in
autumn was higher than in spring in both groups probably due to
higher exposure on the pasture during the summer months. Of note,
the only helminth parasite type found in any of the horses was the
strongyle nematode, which is the most common one for horses. No
other parasites (nematode and cestode) were detected. With regards
to other side effects, we did not observe health issues possibly related
to the vaccine. In particular, no indication for immune complex disease
was found, neither on the skin nor by blood chemistry kidney parame-
ters (blood urea, serum creatinine, albumin, total protein, sodium,
potassium, sodium/potassium ratio, calcium, phosphate) before and
after each IBH season (data not shown).
4 | DISCUSSION
In the present study, we demonstrate that targeting eosinophils by
vaccinating against IL‐5 may be a long‐term therapy for IBH in
horses. We have previously shown a therapeutic effect of this VLP‐
based vaccine in a one‐year placebo‐controlled clinical study.9 Here,
we report that vaccination can be successfully performed over a sec-
ond season and that antibody responses are more long‐lived in the
second treatment year. Thus, the benefit of cytokine‐blocking anti-
bodies normally used in humans by means of mAbs can be brought
to large companion animals, such as horses, by way of active vacci-
nation. Indeed, the size and weight of a horse precludes usage of
mAbs due to excessive costs of such a therapy based on passive
vaccination, which would require frequent injection of very high
amounts of antibodies. In contrast to mAbs, our therapeutic vaccine
is injected at low doses and after the initial first year treatment con-
sisting of a basic vaccination regimen with three injections, the pre-
sent study shows that one yearly booster is sufficient to maintain
the therapeutic effect during the whole season. Antibody titers
dropped toward end of the IBH season in both first and second
treatment year supporting the reversibility and safety of the
approach.
In naive horses, two initial vaccine injections using eIL‐5‐CuMVTT
at weeks 0 and 4 prior to IBH season successfully induced anti‐self
antibodies against eIL‐5. The vaccine booster in the middle of the
season at week 19 increased antibody titers that had been dropping
by that time. Thus, the third injection was necessary for prolonging
antibody titers in the first season. Interestingly, mean anti‐IL‐5 anti-
body titers were one log higher than mean anti‐CuMVTT antibody
titers most likely due to the efficient coupling of IL‐5 to the VLPs.30
In contrast to the horses in the previous study that received five
immunizations in the first treatment year (Ref. 9), peak levels were
higher but had a more pronounced mid‐season drop. Nevertheless,
the clinical efficacy measured by ISI score showed stronger protec-
tion using the three injection regimen over the five injection regi-
men, although the vaccine preparation was slightly different in the
five injection year. For follow‐up 2nd year vaccination, one vaccine
booster using eIL‐5‐CuMVTT successfully induced long‐lasting anti‐
self antibodies against IL‐5. Anti‐IL‐5 antibody titers correlated well
to CuMVTT‐titers, which is consistent with observations in humans
immunized against IL‐1β and may indicate that T cell help rather
than B cells were the limiting factor to drive the IgG responses
against both eIL‐5 and VLP.31 In addition, these data demonstrate
that high anti‐CuMVTT titers do not inhibit induction of IL‐5‐specific
antibodies. Anti‐IL‐5 antibody titers were slightly more variable than
anti‐CuMVTT titers. This may be explained by the notion that anti‐IL‐
5 antibodies may bind to host‐IL‐5 in the serum and that such anti-
bodies in antigen‐antibody complexes may no longer be detectable
by ELISA. The natural variations in levels of IL‐5 between subjects
will perhaps lead to different rates of depletion of anti‐IL‐5 antibod-
ies and hence give a perception of variability in anti‐IL‐5 antibody
responses, as compared to CuMVTT. This is further supported by a
tendency of increasing antibody titers against IL‐5 toward the end of
the season in the 2nd year vaccinated horses in the absence of fur-
ther vaccinations.
Based on in silico prediction analysis, the antibodies induced by
eIL‐5‐CuMVTT vaccination are suggested to recognize comparable
epitopes as the IL‐5 neutralizing human monoclonal antibody res-
lizumab. Thus, the induced antibodies are expected to interfere with
binding of IL‐5 to the IL‐5‐receptor.
In the normal physiological state, enhanced numbers of eosino-
phils are only found in blood when increased numbers of eosinophils
are required in tissues. The eosinophil has three life phases, the bone
marrow, blood, and final tissue phase. The blood‐to‐tissue ratio in
humans is about 1:100.32 The blood phase is considered merely to
F IGURE 6 Improvement of IBH severity score (ISI) by vaccination
with eIL‐5‐CuMVTT vaccine. A & B, All graphs include all horses,
n = 30 (“Pre‐season”, “1st year”, “2nd year”), independent of
antibody titer: ITT, intention to treat. ISI score with ISI 50 and ISI
75. ISI 50 includes % of horses that improved clinical lesion score by
50% and more, ISI 75 includes % of horses that improve clinical
lesion score by 75% and more. A, ISI 50 (black) and ISI 75 (gray)
score of “1st year” in the blinded study comparing vaccinated (V)
and placebo‐treated (P) horses to “Pre‐season.” B, ISI 50 (black) and
ISI 75 (gray) score of Group 1 (V1) and Group 2 (V2) horses of “2nd
year” to “Pre‐season.” IBH, insect‐bite hypersensitivity
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be a “passing‐through” or “waiting for extravasation” phase in circu-
lation until eosinophils finally reach the tissues or die in the majority
of cases. The life span of an eosinophil in blood ranges between 8
to 18 hours. Tissue life span, however, is considered to range from 2
to 5 day, and cytokines such as IL‐5 or chemokines such as eotaxin
can further increase their life span to weeks. Locally produced IL‐5 is
known to increase eosinophil half‐life in tissues (reviewed in Ref.
33). Vaccination using three injections of eIL‐5‐CuMVTT vaccine in
weeks 0, 4, and 19 statistically significantly reduced blood eosinophil
levels throughout the IBH season when comparing to the previous
placebo treatment season in the same horses. In addition, the course
of eosinophil levels negatively correlated with antibody titers, indi-
cating a causative relation between high antibody titers and low
eosinophil levels.
Clinical scores of eIL‐5‐CuMVTT vaccinated horses were found to
be strongly decreased when compared to pre‐treatment season.
Group 1 de novo vaccinated horses showed statistically significantly
reduced clinical signs compared to previous placebo‐treated season.
Depending on the vaccination regimen and vaccine formulation in “1st
year” therapy, between 50% and 70% of horses reached an ISI 50, a
50% and higher improvement of symptoms. “2nd year” therapy was
able to further increase the 50% response to almost 90%. A 75% and
higher improvement of symptoms was achieved in 20% to 30% in “1st
year” therapy, and almost in 50% of horses in “2nd year” therapy.
Thus, we confirmed a clinical effect during the first year vaccination
(basic vaccination) and a continuous and even stronger clinical benefit
in the follow‐up year, which can be explained by more stable and long‐
lasting antibody titers and perhaps increased affinity.
Vaccination with eIL‐5‐CuMVTT was safe and well tolerated.
There was no difference in helminth presence found during the
study period when comparing first year and second year vaccinated
horses, indicating that eosinophil effector function against parasites
is not dramatically impaired. Furthermore, it has been shown that
eosinophil recruitment to healthy, non‐inflamed tissues and function
of eosinophils within tissues may be IL‐5‐independent, indicating
that homeostatic activities of eosinophils in tissues may not be
impaired. This further supports the safety of the vaccination
approach (Ref. 33,34). In addition, no other side effects were noticed
during the study.
Taken together, eIL‐5‐CuMVTT successfully induced anti‐IL‐5 anti-
bodies and mediated statistically significant reduction of eosinophil
levels in blood upon two initial and one mid‐season booster vaccina-
tion. As a consequence, lesion scores were reduced in vaccinated
horses when compared to the previous year with placebo treatment in
the same horses. Symptoms were significantly reduced in the first
treatment season and even further reduced in the second treatment
season upon a single booster vaccination. Enhanced efficacy in the
second treatment season was paralleled by more sustained antibody
titers. This study suggests a basic vaccination regimen consisting of
three vaccinations in the first year and an annual booster for the fol-
lowing years. Thus, eIL‐5‐CuMVTT may be a safe and effective way to
treat IBH in horses, a finding that may be extended to other species, in
particular humans for the treatment of eosinophilic asthma.
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